验证儿童狼疮特异性目标:确保对年幼、体重较轻儿科患者疾病控制的准确评估
本研究在英国JSLE队列研究的430例儿童起病系统性红斑狼疮(cSLE)患者中,验证了儿童特异性达标目标(cLLDAS、cCR、cCR-0)与成人目标(LLDAS、DORIS 2021缓解)的可达性及对预后的影响。结果显示达成cLLDAS、cCR、cCR-0均显著降低严重复发和新发损伤风险,且儿童与成人目标可达性相当。使用cSLE特异性目标可避免对年幼、体重较轻患者的疾病活动度误判。
要点
- 达成cLLDAS、cCR和cCR-0均与严重复发风险降低相关(HR分别为0.18、0.18、0.17)。
- 达成cLLDAS、cCR和cCR-0均与新发损伤风险降低相关(HR分别为0.22、0.25、0.30)。
- 在年幼、体重较轻患者中,使用成人目标可能导致LLDAS和DORIS缓解的不适当达成。
核心结论
- 本研究验证了新的儿科特异性目标,表明达成cLLDAS、cCR和cCR-0可降低新发损伤和严重复发风险,与成人SLE目标相当。
- 使用cSLE特异性目标可防止儿科患者疾病活动度的误分类,从而对年幼、体重较轻患者实现更准确的疾病控制评估。
研究设计与样本
- 研究为在英国JSLE队列研究患者中进行的验证性分析,共纳入430例cSLE患者。
- 每次访视评估cSLE特异性目标(cLLDAS、cCR、cCR-0)和aSLE特异性目标(LLDAS、DORIS 2021缓解)的达成情况。
- 采用单变量和多变量Prentice-Williams-Peterson(PWP)gap-time模型研究目标达成对新发损伤和严重复发的影响。
主要发现
- 达成cLLDAS(HR 0.18 [95% CI: 0.14, 0.23])、cCR(HR 0.18 [0.13, 0.23])和cCR-0(HR 0.17 [0.13, 0.23])降低严重复发风险(均P < 0.001)。
- 达成cLLDAS(HR 0.22 [0.11, 0.44])、cCR(HR 0.25 [0.13, 0.49])和cCR-0(HR 0.30 [0.15, 0.60])降低新发损伤风险(均P < 0.001)。
- LLDAS和DORIS缓解的不适当达成分别发生在35次和52次访视中,患者分别较年轻(中位年龄7.3岁和8.8岁)和体重较轻(中位体重26.8 kg和37.1 kg),同时泼尼松剂量分别中位0.17 [IQR 0.16-0.24] mg/kg/天和0.13 [IQR 0.11-0.16] mg/kg/天,这些剂量妨碍了cSLE目标的达成。
关键数值与推荐
- cLLDAS、cCR和cCR-0的达成与严重复发风险降低相关,HR分别为0.18(95% CI: 0.14, 0.23)、0.18(0.13, 0.23)和0.17(0.13, 0.23),均P < 0.001。
- cLLDAS、cCR和cCR-0的达成与新发损伤风险降低相关,HR分别为0.22(0.11, 0.44)、0.25(0.13, 0.49)和0.30(0.15, 0.60),均P < 0.001。
- LLDAS和DORIS缓解的不适当达成分别发生在35次和52次访视中,患者中位年龄分别为7.3岁和8.8岁,中位体重分别为26.8 kg和37.1 kg,泼尼松剂量分别为中位0.17 [IQR 0.16-0.24] mg/kg/天和0.13 [IQR 0.11-0.16] mg/kg/天。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To validate novel childhood-onset systemic lupus erythematosus (cSLE) treat-to-target targets including childhood lupus low disease activity state (cLLDAS), cSLE clinical remission on steroids (cCR) and cSLE clinical remission off steroids (cCR-0), as compared with adult-onset SLE (aSLE) targets. METHODS: Attainment of the aforementioned cSLE-specific and aSLE-specific targets (LLDAS, DORIS 2021 Remission) was assessed at each visit in UK JSLE Cohort Study patients. Univariable and multivariable Prentice-Williams-Peterson (PWP) gap-time models investigated the impact of target attainment on new damage and severe flare. RESULTS: The cohort included 430 cSLE patients. Attainability was comparable between corresponding cSLE and aSLE targets. Achieving cLLDAS (hazard ratio [HR] 0.18 [95% CI: 0.14, 0.23]), cCR (HR 0.18 [0.13, 0.23]) and cCR-0 (HR 0.17 [0.13, 0.23]) reduced the risk of severe flare (all P < 0.001). Risk of new damage was reduced in those reaching cLLDAS (HR 0.22 [0.11, 0.44]), cCR (HR 0.25 [0.13, 0.49]) and cCR-0 (HR 0.30 [0.15, 0.60]) (all P < 0.001). Inappropriate attainment of LLDAS and DORIS remission occurred at 35 and 52 visits, respectively, in younger (median age 7.3 and 8.8 years, respectively) and lighter (median weight 26.8 and 37.1 kg, respectively) patients whilst on prednisolone doses that precluded cSLE target attainment (median 0.17 [IQR 0.16-0.24] and 0.13 [IQR 0.11-0.16] mg/kg/day, respectively). CONCLUSIONS: This study validates novel paediatric-specific targets, demonstrating that achieving cLLDAS, cCR and cCR-0 reduces risks of new damage and severe flare, which is comparable to aSLE targets. Using cSLE-specific targets prevents misclassification of disease activity in paediatric patients, enabling more accurate disease control assessments in younger, lighter patients.
引用
- Sarker C, Jorgensen AL, Tharmaratnam K, et al. Validation of childhood lupus specific targets: ensuring accurate assessment of disease control in younger, lighter paediatric patients. Rheumatology (Oxford). 2025. PMID: 39913509. doi:10.1093/rheumatology/keaf057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。